ASPIRE
WE ARE ASPIRE
WE ARE ASPIRE
Setting out to establish Alzheimer imaging with non-invasive perfusion MRI Establishing Alzheimer imaging with ASL-MRI

Learn more and start today

ASPIRE

Arterial spin labelling Scanner- and Patient-Independent Robust diagnostic Evaluation

ASPIRE will create a novel imaging biomarker for dementia for diagnosis support. Signs of Alzheimer’s (AD) will be detectable at early stages before clinical manifestation. The solution is based on the non-invasive magnetic resonance imaging (MRI) technique “Arterial Spin Labelling” (ASL) combined with scanner calibration, physiological atlas comparison, and artificial intelligence (AI)-based diagnostic support. The technique will simplify the diagnostic process, reduce cost and patient risk.

Software Solutions

Provided services of ASPIRE will include medical image data management, image data evaluation as well as study-individual set-ups for clinical trials and diagnosis.

Cloud Application

ASPIRE services will be available on the secure mTRIAL platform as cloud applications, making them easily accessible. The app usage will be possible for advanced users and beginners.

Biomarker

ASPIRE will offer ASL dementia biomarker software for the support and assessment of researchers as well as clinical experts within clinical trials and for diagnosis.

ASL Phantom

To ensure high quality results, inter-scanner comparability, optimized scanner profiles as well as the validity of the ASL biomarker, ASL scanner calibration and services will be performed by leading phantom experts.

THE VISION

Our vision is to provide a cost-efficient diagnostic tool for dementia based on the non-invasive MRI technique Arterial Spin Labeling (ASL), applicable to radiological data acquired worldwide. ASL is readily available as a product sequence on all modern MRI scanners, and patients with memory complaints routinely undergo MRI examination to rule out anatomical abnormalities. Adding ASPIRE to the clinical workflow is thus an economic and easy solution to support early reliable diagnosis of AD.

View Our Works

Design

THE TEAM

John

mediri GmbH

Clinical Trial Experts

mediri is an agile pioneer of medical imaging. The company translates current research in imaging and analysis methods into better therapies and greater patient well-being.

Jane

VUmc Amsterdam

Biomarker Experts

VU University Medical Center is the embodiment of distinctive patient care, excellence in higher education, and ground-breaking research.

Mike

Gold Standard Phantoms

Phantom Experts

Gold Standard Phantoms is a University College London's Institute of Neurology spinout company which is developing, marketing and selling calibration services for Quantitative Medical Imaging.

3
Teams
10
Patents
12+
Contributors
141+
ASL related Publications

Expertise

MTRIAL PLATFORM:

Our web-based mTRIAL platform supports all steps of processing medical image data, from acquisition to evaluation and also the collaboration between all stakeholders of a clinical trial. Study data can be transferred, processed and managed via an intuitive user-interface. The modular design guarantees that your individual requirements will be met.

mTRIAL Overview

WHITEBOX:

WHITEBOX connects clinics and radiological pratices to a secure platform which allows automated AI-supported analysis of medical image data for diagnosis support. A patent has been filed to protect the inherent data security concept. The development of this innovative product is supported by the German Federal Ministry for Economic Affairs and Energy.

WHITEBOX

ExploreASL:

ExploreASL is a pipeline and toolbox for image processing and statistics of arterial spin labeling perfusion MR images. It is designed as a multi-OS, open source, collaborative framework that facilitates cross-pollination between image processing method developers and clinical investigators.

ExploreASL Overview

QASPER Phantom:

QASPER (Quantitative Arterial Spin Labelling Perfusion Reference) is a calibration and quality assurance standard for MRI perfusion measurements using Arterial Spin Labelling (ASL). It simulates the process of delivery of arterial blood to an organ in a controlled and reproducible manner.

QASPER Phantom
×

Johannes Gregori

© 2020 Wirtschaft digital Baden-Württemberg

We have been working on improving all technical aspects of ASL for many years, and all team members share the vision to make this a standard diagnostic tool. The idea for ASPIRE was born, to make this a reality for Alzheimer diagnosis support: a highly relevant indication, where ASL can really make a difference.

Dr. Johannes Gregori, Managing Director mediri GmbH, consortium lead

Prof. Dr. Matthias Günther, CEO

Matthias is a Professor for MR-Physics at the University of Bremen. He is the current CEO of the mediri GmbH, and contributes over 15 years’ experience of R&D in the field of ASL-MRI.

View On Researchgate

Publications

156

Reads

13,176

Citations

4,831

Prof. Dr. Xavier Golay, CEO

Xavier is a Professor of MRI Physics at UCL. He is the current CEO of GSP, and contributes over 20 years’ experience of R&D in the field of MRI, from new imaging techniques to the development of contrast agents.

View On Researchgate

Publications

291

Reads

26,099

Citations

10,723

Dr. Henk Mutsaerts, Assistant Prof.

Henk Mutsaerts is a medical doctor with a passion for image processing. His research focuses on the development of arterial spin labeling (ASL) perfusion MRI as clinical biomarker in aging and aging-related disease. His research is stratified in three trajectories: 1) standardization, 2) differentiation and 3) application of ASL as a biomarker of cognitive decline.

View On Researchgate

Publications

58

Reads

4,660

Citations

590

NEWS

aspire image
aspire image

mediri GmbH

We are proud to announce that one of our research projects was selected for funding within the Europe-wide call EUROSTARS. mediri GmbH is coordinator of the project ASPIRE which will start in May. Within the €2.3 million project we will create a novel imaging biomarker for dementia to support diagnosis together with our strong partners Gold Standard Phantoms and VUmc Amsterdam. Within ASPIRE, we will establish a solution to detect signs of Alzheimer’s disease at early stages before clinical manifestation. We will use Arterial Spin Labelling (ASL) combined with scanner calibration, physiological atlas comparison, and AI-based diagnostic support to simplify the diagnostic process, reduce cost and patient risk.

#dementia #alzheimer #ai #ki #medicalimaging #medicaltechnology #aspiremri

aspire image
neuro image
neuro image

mediri GmbH

Have a look at this milestone article published in Neuroimage describing the ExploreASL pipeline which allows to analyse ASL images across vendors and platforms. Authors are, amongst others, our CEO Matthias Guenther and our ASPIRE project partners Henk(-Jan) Mutsaerts and Xavier Golay.

#aspiremri https://lnkd.in/gga-HE3

neuro image
vumc image
vumc image

Henk(-Jan) Mutsaerts

For those who speak Dutch, how cool, how honored am I and grateful to my colleagues!

Twee subsidies voor minder belastende MRI-methode om diagnose dementie vroegtijdig te stellen.

#aspiremri https://lnkd.in/gyfTZyy

vumc image
vumc aspire image
vumc aspire image

VU University Medical Center - Amsterdam Neuroscience

The ASPIRE (Arterial spin labeling Scanner- and Patient-Independent Robust Evaluation) consortium aims to facilitate brain perfusion imaging by MRI for dementia diagnosis and prognosis in clinical pharmaceutical studies and clinical practice.

They combine the industry's latest advances to provide a robust, non-invasive imaging technique for AD prediction, seamlessly integrated into the standard MRI examination routine. Artificial intelligence (AI) methods will be used to analyze localized disease-specific changes in brain perfusion for diagnosis support. Amsterdam UMC (location VUmc), with Professor Frederik Barkhof and clinical researcher Henk(-Jan) Mutsaerts, leads the development of the advanced ASL analysis software ExploreASL.

#aspiremri academia-and-industry-join-forces-to-establish-non-invasive-perfusion-mri

vumc aspire image

CONTACT

Lets get in touch. Send us a message:

MEDIRI

mediri GmbH

Heidelberg, Germany

Phone: +49 6221 725 6970

Email: info@mediri.com
VUMC

VUmc Amsterdam

Amsterdam, Netherlands

Email: h.j.mutsaerts@amsterdamumc.nl
GSP

Gold Standard Phantoms

London, UK

Email: info@goldstandardphantoms.com

IMPRINT

General Information

The aspire-mri.eu website is provided by the mediri GmbH, Eppelheimer Str. 13, 69115 Heidelberg, Germany. CEO: Prof. Dr. M. Günther, Managing Director: Dr. J. Gregori. Registry court: Amtsgericht Mannheim, HRB 337863. UStID-Nr. DE 238569040.

Feel free to contact our general ASPIRE team using ASPIRE@mediri.com or message an individual ASPIRE project partner using one of the contact forms above.

Funding

The Eurostars-Project ASPIRE 01QE2026A is funded by the Federal Ministry of Education and Research, the Eurostars program as well as Innovate UK.

General Information

The aspire-mri.eu website is provided by the mediri GmbH, Eppelheimer Str. 13, 69115 Heidelberg, Germany. CEO: Prof. Dr. M. Günther, Managing Director: Dr. J. Gregori. Registry court: Amtsgericht Mannheim, HRB 337863. UStID-Nr. DE 238569040.

Feel free to contact our general ASPIRE team using ASPIRE@mediri.com or message an individual ASPIRE project partner using one of the contact forms above.

Funding

The Eurostars-Project ASPIRE 01QE2026A is funded by the Federal Ministry of Education and Research, the Eurostars program as well as Innovate UK.

Sponsored by ...

[BMBF icon] [eurostars icon] [eureka icon] [innovate uk icon]

Terms of Use & Privacy Policy

Regarding our terms of use and the ASPIRE privacy policy, please checkout the fields below or contact our team.

Regarding our terms of use and the ASPIRE privacy policy, please checkout the fields below or contact our team.

&